Compare DFNS & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | HYFT |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 69.6M |
| IPO Year | N/A | N/A |
| Metric | DFNS | HYFT |
|---|---|---|
| Price | $1.44 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 312.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $51.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.51 | $1.05 |
| 52 Week High | $2.68 | $3.00 |
| Indicator | DFNS | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 32.74 |
| Support Level | N/A | N/A |
| Resistance Level | $2.56 | $2.17 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 3.00 | 15.91 |
T3 Defense Inc is a world-wide aerospace and defense federated holding company focused on acquiring and operating mission-critical defense businesses embedded at critical chokepoints of long-cycle national security programs. Through disciplined M&A, centralized capital and ideas, and decentralized operating autonomy, it aims to build an asymmetric edge by strengthening critical defense capabilities and compounding long-term value.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.